Nuwellis Crescita futura

Future criteri di controllo 2/6

Si prevede che Nuwellis aumenterà gli utili e i ricavi rispettivamente del 61.9% e 36.3% all'anno, mentre si prevede che l'EPS crescerà del 87.1% all'anno.

Informazioni chiave

61.9%

Tasso di crescita degli utili

87.1%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	15.7%
Tasso di crescita dei ricavi	36.3%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	28 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

DB:22S - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	17	-6	N/A	N/A	1
12/31/2025	11	-10	N/A	N/A	2
12/31/2024	9	-15	N/A	N/A	2
6/30/2024	9	-23	-12	-12	N/A
3/31/2024	9	-20	-15	-15	N/A
12/31/2023	9	-23	-18	-18	N/A
9/30/2023	9	-17	-19	-18	N/A
6/30/2023	8	-17	-18	-18	N/A
3/31/2023	8	-17	-17	-16	N/A
12/31/2022	9	-15	-15	-15	N/A
9/30/2022	8	-17	-16	-16	N/A
6/30/2022	8	-18	-18	-17	N/A
3/31/2022	8	-19	-18	-17	N/A
12/31/2021	8	-20	-18	-18	N/A
9/30/2021	8	-18	-17	-17	N/A
6/30/2021	8	-17	-17	-17	N/A
3/31/2021	8	-17	-17	-16	N/A
12/31/2020	7	-18	-17	-17	N/A
9/30/2020	7	-19	-17	-17	N/A
6/30/2020	6	-19	-17	-16	N/A
3/31/2020	6	-20	-17	-17	N/A
12/31/2019	6	-23	-17	-16	N/A
9/30/2019	6	-22	-16	-15	N/A
6/30/2019	6	-22	-15	-15	N/A
3/31/2019	5	-22	-15	-14	N/A
12/31/2018	5	-17	-15	-15	N/A
9/30/2018	4	-29	-15	-15	N/A
6/30/2018	4	-27	-15	-15	N/A
3/31/2018	4	-27	N/A	-15	N/A
12/31/2017	4	-25	N/A	-12	N/A
9/30/2017	3	-14	N/A	-11	N/A
6/30/2017	3	-15	N/A	-13	N/A
3/31/2017	2	-16	N/A	-12	N/A
12/31/2016	1	-18	N/A	-16	N/A
9/30/2016	1	-19	N/A	-18	N/A
6/30/2016	N/A	-22	N/A	-19	N/A
3/31/2016	N/A	-24	N/A	-22	N/A
12/31/2015	0	-27	N/A	-23	N/A
9/30/2015	0	-27	N/A	-24	N/A
6/30/2015	0	-26	N/A	-24	N/A
3/31/2015	0	-26	N/A	-23	N/A
12/31/2014	0	-26	N/A	-23	N/A
9/30/2014	0	-26	N/A	-23	N/A
6/30/2014	0	-26	N/A	-22	N/A
3/31/2014	0	-24	N/A	-20	N/A
12/31/2013	0	-22	N/A	-17	N/A
9/30/2013	0	-19	N/A	-15	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che 22S rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che 22S rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che 22S rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 22S ( 36.3% all'anno) crescerà più rapidamente del mercato German ( 5.5% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 22S ( 36.3% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di 22S è previsto essere elevato tra 3 anni

Nuwellis Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Nuwellis Provides Revenue Guidance for Third Quarter Ended September 30, 2024

Nuwellis, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Nuwellis, Inc. Provides Product Revenue Guidance for the Three Months Ended September 30, 2022

Nuwellis, Inc. Provides Revenue Guidance for the Full Year 2021

Recent updates

Nuwellis Provides Revenue Guidance for Third Quarter Ended September 30, 2024

Nuwellis, Inc. to Report Q3, 2024 Results on Nov 11, 2024

Seastar Medical Holding Corporation Enters into Confidential Settlement Agreement and Release with Nuwellis

Nuwellis, Inc. has completed a Follow-on Equity Offering in the amount of $0.891783 million.

Nuwellis, Inc. has filed a Follow-on Equity Offering in the amount of $0.916782 million.

Nasdaq Panel Grants Nuwellis Continued Listing on the Nasdaq Stock Market, Subject to Conditions

Nuwellis Announces First Pediatric Patient Treated in A Commercial Setting with Seastar Medical's Quelimune Therapy At Cincinnati Children's

Nuwellis, Inc. has filed a Follow-on Equity Offering in the amount of $1.990002 million.

Nuwellis, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Nuwellis Marks First Commercial Sale of Quelimune Therapy to Cincinnati Children's

Nuwellis, Inc. Announces New Clinical Evidence Demonstrating the Efficacy of its Aquadex® System to be Presented at HFSA 2024 Conference

Nuwellis Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement

First quarter 2024 earnings released: US$0.78 loss per share (vs US$5.76 loss in 1Q 2023)

Nuwellis, Inc. Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology

Nuwellis, Inc. to Report Q1, 2024 Results on May 07, 2024

Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health

Nuwellis, Inc. Announces Results from Two New Clinical Data Analyses from the AVOID-HF Trial, Which Demonstrate the Benefits of its Aquadex System in Reducing Heart Failure Readmissions at 30 Days

Full year 2023 earnings released: US$11.52 loss per share (vs US$83.48 loss in FY 2022)

Nuwellis, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Nuwellis, Inc. Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter

Nuwellis Receives Non-Compliance Notice from Nasdaq

Nuwellis, Inc. Announces New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring Foriatric Patients

Third quarter 2023 earnings released: US$1.81 loss per share (vs US$36.72 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Less than half of directors are independent

Nuwellis, Inc. Announces Board of Directors Transition

Nuwellis, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Nuwellis, Inc. has completed a Composite Units Offering in the amount of $2.25 million.

Nuwellis Provides Regulatory Update on Seastar Medical's Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under A Humanitarian Device Exemption

Nuwellis, Inc. Appoints Robert B. Scott as Chief Financial Officer, Effective September 2, 2023

Second quarter 2023 earnings released: US$3.65 loss per share (vs US$40.67 loss in 2Q 2022)

Nuwellis, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Revenue and earnings growth

Nuwellis, Inc. Announces the Appointment of Mike Mccormick to its Board of Directors

First quarter 2023 earnings released: US$5.76 loss per share (vs US$42.45 loss in 1Q 2022)

Full year 2022 earnings released: US$83.48 loss per share (vs US$287 loss in FY 2021)

Nuwellis, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Nuwellis, Inc. Announces Board Changes

Nuwellis, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Nuwellis Appoints John Jefferies as Chief Medical Officer

Nuwellis Announces Compliance with Nasdaq Listing Requirements

Nuwellis, Inc. Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

Insufficient new directors

Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.74 loss in 3Q 2021)

Nuwellis, Inc. Announces Peer Reviewed Data Demonstrating 71% Survival with Kidney Replacement Therapy Using A Modified Aquadex in Low-Birth-Weight Preterm Neonates

Insufficient new directors

Nuwellis, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Nuwellis, Inc. Provides Product Revenue Guidance for the Three Months Ended September 30, 2022

Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality At the 2022 Hfsa Meeting

Insufficient new directors

Nuwellis, Inc. Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial

Nuwellis, Inc. Announces Executive Changes

Nuwellis, Inc. Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients

Nuwellis, Inc. Announces U.S. Patent and Trademark Office Awards Patent for Innovative Pediatric Technology

Second quarter 2022 earnings released: US$0.41 loss per share (vs US$0.72 loss in 2Q 2021)

Nuwellis, Inc Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA

Nuwellis, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Nuwellis, Inc. Announces First Patient Enrolled in Its Pivotal Trial REVERSE-HF

Nuwellis Receives a Letter from the Listing Qualifications Department of Nasdaq Regarding Minimum Bid Price Requirement

First quarter 2022 earnings released: US$0.42 loss per share (vs US$1.25 loss in 1Q 2021)

Nuwellis, Inc. to Report Q1, 2022 Results on May 10, 2022

Nuwellis, Inc., Annual General Meeting, May 17, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Nuwellis, Inc. Initiates REVERSE-HF Study to Evaluate Ultrafiltration for Heart Failure Patients with Fluid Overload

Nuwellis, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Nuwellis, Inc. Provides Revenue Guidance for the Full Year 2021

Nuwellis Provides More Children in Texas With Access to Its Unique Fluid Management Technology

CHF Solutions Submits Patent Application for New Peripheral Venous Access Technology for Ultrafiltration and CRRT Systems

Chf Solutions Expands Access to Ultrafiltration Therapy for Pediatric Patients in Puerto Rico

CHF Solutions, Inc. to Report Q4, 2020 Results on Mar 02, 2021

CHF Solutions, Inc. Submits Patent Application for New and Improved Diagnostic Parameters to Support Hemodynamic Stability